Johnson & Johnson, a fourth vaccine for Europe which brings a real novelty

LEuropean countries will soon be able to rely on an additional vaccine to speed up the tempo of their vaccination campaign. On Thursday, the European Commission gave the green light for the conditional marketing of Johnson & Johnson’s vaccine against Covid-19, which had received a positive evaluation a few hours earlier from the EMA’s Committee for Medicinal Products for Human Use ( European Medicines Agency). The health authority considered that the benefits outweighed the risks. It is the fourth vaccine to be authorized on European soil (after those of Pfizer, Moderna and AstraZeneca). Three others are still under review: CureVac, Novavax and the Russian vaccine Sputnik V.

Leave a Reply

Your email address will not be published. Required fields are marked *